vs
Liberty Broadband Corp（LBRDA）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是Orthofix Medical Inc.的1.2倍（$261.0M vs $219.9M），Liberty Broadband Corp净利率更高（146.7% vs -1.0%，领先147.8%），Liberty Broadband Corp同比增速更快（6.1% vs 2.0%），Liberty Broadband Corp自由现金流更多（$37.0M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.3%）
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
LBRDA vs OFIX — 直观对比
营收规模更大
LBRDA
是对方的1.2倍
$219.9M
营收增速更快
LBRDA
高出4.1%
2.0%
净利率更高
LBRDA
高出147.8%
-1.0%
自由现金流更多
LBRDA
多$20.2M
$16.8M
两年增速更快
OFIX
近两年复合增速
4.3%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.0M | $219.9M |
| 净利润 | $383.0M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 15.7% | 0.2% |
| 净利率 | 146.7% | -1.0% |
| 营收同比 | 6.1% | 2.0% |
| 净利润同比 | 96.4% | 92.4% |
| 每股收益（稀释后） | $2.68 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LBRDAOFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | — | $205.6M | ||
| Q2 25 | $261.0M | $203.1M | ||
| Q1 25 | $266.0M | $193.6M | ||
| Q4 24 | $263.0M | $215.7M | ||
| Q3 24 | $262.0M | $196.6M | ||
| Q2 24 | $246.0M | $198.6M | ||
| Q1 24 | $245.0M | $188.6M |
净利润LBRDAOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | — | $-22.8M | ||
| Q2 25 | $383.0M | $-14.1M | ||
| Q1 25 | $268.0M | $-53.1M | ||
| Q4 24 | $291.0M | $-29.1M | ||
| Q3 24 | $142.0M | $-27.4M | ||
| Q2 24 | $195.0M | $-33.4M | ||
| Q1 24 | $241.0M | $-36.0M |
毛利率LBRDAOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率LBRDAOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | 15.7% | -7.9% | ||
| Q1 25 | 16.2% | -25.2% | ||
| Q4 24 | 4.9% | -5.3% | ||
| Q3 24 | 11.5% | -9.6% | ||
| Q2 24 | 8.5% | -12.5% | ||
| Q1 24 | 11.4% | -15.6% |
净利率LBRDAOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | — | -11.1% | ||
| Q2 25 | 146.7% | -6.9% | ||
| Q1 25 | 100.8% | -27.4% | ||
| Q4 24 | 110.6% | -13.5% | ||
| Q3 24 | 54.2% | -13.9% | ||
| Q2 24 | 79.3% | -16.8% | ||
| Q1 24 | 98.4% | -19.1% |
每股收益（稀释后）LBRDAOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | $2.68 | $-0.36 | ||
| Q1 25 | $1.87 | $-1.35 | ||
| Q4 24 | $2.04 | $-0.76 | ||
| Q3 24 | $0.99 | $-0.71 | ||
| Q2 24 | $1.36 | $-0.88 | ||
| Q1 24 | $1.69 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $82.0M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $10.4B | $450.0M |
| 总资产 | $16.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资LBRDAOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | $180.0M | $65.6M | ||
| Q1 25 | $226.0M | $58.0M | ||
| Q4 24 | $163.0M | $83.2M | ||
| Q3 24 | $168.0M | $30.1M | ||
| Q2 24 | $73.0M | $26.4M | ||
| Q1 24 | $108.0M | $27.0M |
总债务LBRDAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | $3.1B | $157.0M | ||
| Q1 25 | $3.8B | $156.9M | ||
| Q4 24 | $3.8B | $157.0M | ||
| Q3 24 | $3.7B | $118.5M | ||
| Q2 24 | $3.6B | $118.0M | ||
| Q1 24 | $3.6B | $118.2M |
股东权益LBRDAOFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | — | $442.5M | ||
| Q2 25 | $10.4B | $458.3M | ||
| Q1 25 | $10.1B | $458.3M | ||
| Q4 24 | $9.8B | $503.1M | ||
| Q3 24 | $9.5B | $525.9M | ||
| Q2 24 | $9.3B | $546.0M | ||
| Q1 24 | $9.1B | $570.3M |
总资产LBRDAOFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | — | $832.6M | ||
| Q2 25 | $16.6B | $837.2M | ||
| Q1 25 | $17.0B | $823.1M | ||
| Q4 24 | $16.7B | $893.3M | ||
| Q3 24 | $16.3B | $867.9M | ||
| Q2 24 | $16.0B | $882.0M | ||
| Q1 24 | $15.7B | $906.0M |
负债/权益比LBRDAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | 0.30× | 0.34× | ||
| Q1 25 | 0.38× | 0.34× | ||
| Q4 24 | 0.38× | 0.31× | ||
| Q3 24 | 0.39× | 0.23× | ||
| Q2 24 | 0.39× | 0.22× | ||
| Q1 24 | 0.40× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $91.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 14.2% | 7.6% |
| 资本支出强度资本支出/营收 | 20.7% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.24× | — |
| 过去12个月自由现金流最近4个季度 | $-49.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流LBRDAOFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | — | $12.4M | ||
| Q2 25 | $91.0M | $11.6M | ||
| Q1 25 | $78.0M | $-18.4M | ||
| Q4 24 | $1.0M | $23.7M | ||
| Q3 24 | $24.0M | $11.7M | ||
| Q2 24 | $27.0M | $9.0M | ||
| Q1 24 | $52.0M | $-18.6M |
自由现金流LBRDAOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $37.0M | $4.5M | ||
| Q1 25 | $13.0M | $-25.1M | ||
| Q4 24 | $-63.0M | $15.2M | ||
| Q3 24 | $-36.0M | $6.3M | ||
| Q2 24 | $-35.0M | $-360.0K | ||
| Q1 24 | $-9.0M | $-29.1M |
自由现金流率LBRDAOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 14.2% | 2.2% | ||
| Q1 25 | 4.9% | -13.0% | ||
| Q4 24 | -24.0% | 7.0% | ||
| Q3 24 | -13.7% | 3.2% | ||
| Q2 24 | -14.2% | -0.2% | ||
| Q1 24 | -3.7% | -15.4% |
资本支出强度LBRDAOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | 20.7% | 3.5% | ||
| Q1 25 | 24.4% | 3.5% | ||
| Q4 24 | 24.3% | 4.0% | ||
| Q3 24 | 22.9% | 2.7% | ||
| Q2 24 | 25.2% | 4.7% | ||
| Q1 24 | 24.9% | 5.6% |
现金转化率LBRDAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LBRDA
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
